A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRDN SEC filings page.
Guardian Pharmacy Services, Inc. (GRDN) reported $1.4B in revenue for fiscal year 2025, up 17.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025's profitability turnaround came mainly from lower overhead relative to sales, while cash generation and liquidity strengthened without debt.
Revenue grew17.9% while gross margin widened only0.3 percentage points . Meanwhile, SG&A fell from25.0% to15.2% of revenue, indicating the turnaround was driven primarily by overhead absorption rather than a major change in gross economics.
FY2025 net income was
Current ratio improved from 1.1x to 1.4x, giving FY2025 more short-term asset coverage. Long-term debt remained
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Guardian Pharmacy Services, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Guardian Pharmacy Services, Inc. scores 26/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Guardian Pharmacy Services, Inc. scores 79/100 on it among other operating companies.
Guardian Pharmacy Services, Inc. reported no long-term debt at the end of fiscal year 2025 and held $65.6M of cash. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Guardian Pharmacy Services, Inc. scores 87/100 among other operating companies measured the same way.
Guardian Pharmacy Services, Inc. held $1.38 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.38. Liquidity ranks operating companies on that ratio, and Guardian Pharmacy Services, Inc. scores 38/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Guardian Pharmacy Services, Inc. scores 46/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Guardian Pharmacy Services, Inc. scores 33/100 on it among other operating companies.
Guardian Pharmacy Services, Inc. scores 13.66, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $3.0B against total liabilities of $194.7M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Guardian Pharmacy Services, Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Guardian Pharmacy Services, Inc. generates $2.04 in operating cash flow ($100.3M OCF vs $49.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Guardian Pharmacy Services, Inc. earns $109.32 in operating income for every $1 of interest expense ($72.7M vs $665K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Guardian Pharmacy Services, Inc. generated $371.1M in revenue in Q3 2026. This represents a decrease of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 5.5%.
Guardian Pharmacy Services, Inc.'s EBITDA was $31.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 39.7% from the same quarter a year earlier. Against the prior quarter it is up 17.2%.
Guardian Pharmacy Services, Inc. reported $18.7M in net income in Q3 2026. This represents an increase of 90.3% from the same quarter a year earlier. Against the prior quarter it is down 14.6%.
Guardian Pharmacy Services, Inc. earned $0.29 per diluted share (EPS) in Q3 2026. This represents an increase of 93.3% from the same quarter a year earlier.
Cash & Balance Sheet
Guardian Pharmacy Services, Inc. held $119.7M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Guardian Pharmacy Services, Inc.'s gross margin was 23.0% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.
Guardian Pharmacy Services, Inc.'s operating margin was 6.8% in Q3 2026, reflecting core business profitability. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
Guardian Pharmacy Services, Inc.'s net profit margin was 5.0% in Q3 2026, showing the share of revenue converted to profit. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.
Guardian Pharmacy Services, Inc.'s quarterly ROE was 7.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.
Capital Allocation
None of these metrics is reported for Q3 2026.
GRDN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $371.1M-1.7% | $351.8M+2.2% | $336.6M+2.2% | $397.6M+17.4% | $377.4M+20.0% | $344.3M+14.8% | $329.3M+19.6% | $338.6M |
| Cost of Revenue | $285.8M-5.6% | $271.7M-1.6% | $260.3M-1.8% | $312.1M+15.0% | $302.7M+19.4% | $276.2M+15.7% | $265.0M+20.3% | $271.5M |
| Gross Profit | $85.2M+14.1% | $80.0M+17.5% | $76.3M+18.6% | $85.5M+27.4% | $74.7M+22.7% | $68.1M+11.2% | $64.3M+16.8% | $67.1M |
| SG&A Expenses | $60.2M+3.1% | $59.4M+6.9% | $58.6M+14.2% | $54.7M+8.7% | $58.4M-64.7% | $55.6M+25.5% | $51.3M+8.9% | $50.3M |
| Operating Income | $25.1M+53.3% | $20.6M+64.1% | $17.7M+35.9% | $30.8M+83.6% | $16.4Mn/m | $12.6M-26.0% | $13.0M+63.9% | $16.8M |
| EBITDA | $31.0M+39.7% | $26.5M+46.4% | $23.7M+29.4% | $36.5M+66.6% | $22.2Mn/m | $18.1M-17.4% | $18.3M+44.1% | $21.9M |
| Interest Expense | $177K+10.6% | $154K-10.5% | $154K-9.4% | $163K-61.3% | $160K-84.4% | $172K-83.9% | $170K-77.8% | $421K |
| Income Tax | $6.9M-2.6% | $7.7M+104.0% | $4.7M+23.9% | $9.8M+124.5% | $7.0M+3898.9% | $3.8Mn/m | $3.8Mn/m | $4.4M |
| Net Income | $18.7M+90.3% | $21.9M+142.2% | $13.3M+40.7% | $20.9M+75.2% | $9.8Mn/m | $9.0Mn/m | $9.4M+239.1% | $11.9M |
| EPS (Basic) | $0.29+81.2% | N/A | N/A | N/A | $0.16 | N/A | N/A | N/A |
| EPS (Diluted) | $0.29+93.3% | N/A | N/A | N/A | $0.15 | N/A | N/A | N/A |
| Diluted Shares (Avg) | 64M+0.8% | N/A | N/A | N/A | 63M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses.
GRDN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $491.8M+26.1% | $443.6M+24.5% | $426.9M+27.8% | $412.7M+28.6% | $390.0M+12.1% | $356.3M | $334.0M | $320.8M+18.3% |
| Current Assets | $294.8M+48.7% | $254.7M+49.4% | $235.2M+41.6% | $221.6M+45.8% | $198.3M+10.0% | $170.5M | $166.0M | $152.0M+17.3% |
| Cash & Equivalents | $119.7M+227.9% | $89.8M+377.3% | $64.9M+363.6% | $65.6M+1308.1% | $36.5M-2.0% | $18.8M+1123.5% | $14.0M+7945.4% | $4.7M+519.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $57.1M+19.2% | $50.4M+14.2% | $47.2M+8.6% | $43.4M+6.9% | $47.9M+5.8% | $44.2M | $43.4M | $40.5M+10.4% |
| Accounts Receivable | $107.7M+1.4% | $103.8M+10.2% | $111.7M+14.7% | $101.6M+4.6% | $106.2M+16.8% | $94.1M | $97.4M | $97.2M+25.7% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $82.0M+3.0% | $79.7M+4.7% | $79.7M+15.1% | $79.7M+15.1% | $79.6M+16.3% | $76.2M | $69.3M | $69.3M+23.6% |
| Total Liabilities | $212.1M+9.0% | $185.9M+5.2% | $194.5M+13.9% | $194.7M+14.0% | $194.5M-9.1% | $176.7M | $170.8M | $170.8M-19.2% |
| Current Liabilities | $179.1M+10.6% | $154.0M+7.0% | $160.5M+10.5% | $160.7M+11.5% | $161.9M+2.3% | $144.0M | $145.3M | $144.1M+4.4% |
| Non-Current Liabilities | $33.0M+1.2% | $31.9M-2.4% | $34.0M+33.3% | $34.0M+27.4% | $32.6M-41.6% | $32.7M | $25.5M | $26.7M-63.6% |
| Long-Term Debt | N/A | N/A | N/A | $0n/m | N/A | N/A | N/A | $0-100.0% |
| Total Equity | $267.2M+45.4% | $245.6M+44.9% | $220.9M+41.5% | $205.8M+44.2% | $183.8M+44.0% | $169.6M | $156.1M | $142.7M+405.8% |
| Retained Earnings | $120.2M+164.6% | $101.5M+185.1% | $79.6M+199.7% | $66.3M+287.4% | $45.4M+776.7% | $35.6M | $26.6M | $17.1M |
GRDN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $43.4M+54.0% | $30.0M+50.6% | $6.1M-65.5% | $34.6M+54.9% | $28.2Mn/m | $19.9M-31.6% | $17.6M+102.8% | $22.3M |
| Depreciation & Amortization | $5.9M+1.6% | $5.8M+5.8% | $6.0M+13.5% | $5.7M+11.4% | $5.8M+16.9% | $5.5M+12.6% | $5.3M+10.9% | $5.2M |
| Stock-Based Compensation | $2.7M-37.2% | N/A | $1.9M-53.1% | N/A | $4.4M-96.4% | $4.4Mn/m | $4.0M-33.3% | N/A |
| Capital Expenditures | N/A | N/A | N/A | $495K-78.0% | $4.0M+80.5% | N/A | N/A | $2.3M |
| Free Cash Flow | N/A | N/A | N/A | $34.1M+69.8% | $24.2Mn/m | N/A | N/A | $20.1M |
| Investing Cash Flow | -$10.9Mn/m | -$4.3Mn/m | -$4.8Mn/m | -$4.7Mn/m | -$9.0Mn/m | -$13.0Mn/m | -$5.5Mn/m | -$6.6M |
| Financing Cash Flow | -$2.6Mn/m | -$805Kn/m | -$2.0Mn/m | -$758Kn/m | -$1.5M-103.4% | -$2.1Mn/m | -$2.7Mn/m | -$48.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GRDN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.0%+3.2pp | 22.8%+3.0pp | 22.7%+3.1pp | 21.5%+1.7pp | 19.8%+0.4pp | 19.8%-0.6pp | 19.5%-0.5pp | 19.8% |
| Operating Margin | 6.8%+2.4pp | 5.9%+2.2pp | 5.3%+1.3pp | 7.7%+2.8pp | 4.3%+37.6pp | 3.6%-2.0pp | 4.0%+1.1pp | 5.0% |
| Net Margin | 5.0%+2.4pp | 6.2%+3.6pp | 4.0%+1.1pp | 5.3%+1.7pp | 2.6%+41.4pp | 2.6%+2.6pp | 2.9%+1.9pp | 3.5% |
| Return on Equity | 7.0%+1.7pp | 8.9%+3.6pp | 6.0%0.0pp | 10.2%+1.8pp | 5.3%+101.0pp | 5.3% | 6.0% | 8.4% |
| Return on Assets | 3.8%+1.3pp | 4.9%+2.4pp | 3.1%+0.3pp | 5.1%+1.4pp | 2.5%+37.6pp | 2.5% | 2.8% | 3.7% |
| Current Ratio | 1.65+0.4x | 1.65+0.5x | 1.46+0.3x | 1.38+0.3x | 1.22+0.1x | 1.18 | 1.14 | 1.05+0.1x |
| Debt-to-Equity | N/A | N/A | N/A | 0.000.0x | N/A | N/A | N/A | 0.00-0.7x |
| Liabilities-to-Equity | 0.79-0.3x | 0.76-0.3x | 0.88-0.2x | 0.95-0.3x | 1.06-0.6x | 1.04 | 1.09 | 1.20-6.3x |
| Asset Turnover | 0.75-0.2x | 0.79-0.2x | 0.79-0.2x | 0.96-0.1x | 0.97+0.1x | 0.97 | 0.99 | 1.06 |
| FCF Margin | N/A | N/A | N/A | 8.6%+2.7pp | 6.4%+7.8pp | N/A | N/A | 5.9% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc. GRDN | FY2025 | $1.4B | $49.2M | 3.4% | $3.0B | 52/100 |
| Acadia Healthcare Company, Inc. ACHC | FY2025 | $3.3B | -$1.1B | -33.3% | $3.2B | 27/100 |
| National Healthcare Corp. NHC | FY2025 | $1.5B | $120.0M | 7.9% | $3.0B | 65/100 |
| Surgery Partners, Inc. SGRY | FY2025 | $3.3B | -$77.9M | -2.4% | $3.5B | 54/100 |
| Aveanna Healthcare Holdings Inc. AVAH | FY2026 | $2.4B | $225.0M | 9.3% | $2.4B | 44/100 |
| Addus HomeCare Corp. ADUS | FY2025 | $1.4B | $95.9M | 6.7% | $2.3B | 68/100 |
Where Guardian Pharmacy Services, Inc. Ranks
Frequently Asked Questions
Guardian Pharmacy Services, Inc. (GRDN) reported $1.4B in total revenue for fiscal year 2025. This represents a 17.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Guardian Pharmacy Services, Inc. (GRDN) revenue grew by 17.9% year-over-year, from $1.2B to $1.4B in fiscal year 2025.
Yes, Guardian Pharmacy Services, Inc. (GRDN) reported a net income of $49.2M in fiscal year 2025, with a net profit margin of 3.4%.
Guardian Pharmacy Services, Inc. (GRDN) had EBITDA of $95.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Guardian Pharmacy Services, Inc. (GRDN) had $65.6M in cash and equivalents against $0 in long-term debt.
Guardian Pharmacy Services, Inc. (GRDN) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Guardian Pharmacy Services, Inc. (GRDN) had an operating margin of 5.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Guardian Pharmacy Services, Inc. (GRDN) had a net profit margin of 3.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Guardian Pharmacy Services, Inc. (GRDN) has a return on equity of 23.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Guardian Pharmacy Services, Inc. (GRDN) generated $86.8M in free cash flow during fiscal year 2025. This represents a 100.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Guardian Pharmacy Services, Inc. (GRDN) generated $100.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Guardian Pharmacy Services, Inc. (GRDN) had $412.7M in total assets as of fiscal year 2025, including both current and long-term assets.
Guardian Pharmacy Services, Inc. (GRDN) invested $13.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Guardian Pharmacy Services, Inc. (GRDN) had a current ratio of 1.38 as of fiscal year 2025, which is considered adequate.
Guardian Pharmacy Services, Inc. (GRDN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Guardian Pharmacy Services, Inc. (GRDN) had a liabilities-to-equity ratio of 0.95 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Guardian Pharmacy Services, Inc. (GRDN) had a return on assets of 11.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Guardian Pharmacy Services, Inc. (GRDN) trades at 39.8x earnings, its market capitalization divided by $74.8M net income, trailing 12 months to September 30, 2026. The market capitalization is $3.0B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Guardian Pharmacy Services, Inc. (GRDN) trades at 2.0x sales, its market capitalization divided by $1.5B revenue, trailing 12 months to September 30, 2026. The market capitalization is $3.0B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Guardian Pharmacy Services, Inc. (GRDN) has an Altman Z-Score of 13.66, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Guardian Pharmacy Services, Inc. (GRDN) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Guardian Pharmacy Services, Inc. (GRDN) has an earnings quality ratio of 2.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Guardian Pharmacy Services, Inc. (GRDN) has an interest coverage ratio of 109.32x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Guardian Pharmacy Services, Inc. (GRDN) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.